#vaccine research

Messenger RNA vaccines—also called mRNA vaccines—are some of the first COVID-19 vaccines authorized for use in the United States.

The vaccine demonstrated 95% efficacy in an ongoing Phase III trial.

Vaccine development is proceeding at an unprecedented pace, but could still hit snags on the way to approval.

The front-runner coronavirus vaccine appears to protect people from symptomatic disease.

The trial is evaluating an investigational vaccine from Janssen that may require only one shot.

FDA weighs whether to resume coronavirus vaccine trial halted due to an adverse event.

A U.K. woman developed spinal inflammation after receiving an adenovirus vector vaccine.

The World Health Organization coordinates efforts to create flu and COVID-19 vaccines and to fight other global health issues.

The trial will enroll healthy volunteers to test the vaccine’s safety and ability to trigger an immune response.

Some study participants experienced hepatitis B surface antigen loss, considered a functional cure.

Sci-B-Vac may offer more protection for older people and those with a weaker immune system.

People who received the vaccine did, however, show stronger immune responses against the virus.

Ending the week with summaries of research from the 2018 Liver Meeting. I cover hepatitis B vaccination, diet and alcoholic liver disease.

A hep C–like virus in the city’s rodents is being used to create the first animal model of the human disease.

The FDA has once again rejected the California-based biotech’s request to approve Heplisav-B.